Latest News and Press Releases
Want to stay updated on the latest news?
-
-- New name completes successful integration process -- Additional investment expected to build platform for future growth REYKJAVIK, Iceland, April 26, 2007 (PRIME NEWSWIRE) -- Actavis Group...
-
REYKJAVIK, Iceland, March 1, 2007 (PRIME NEWSWIRE) -- Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceuticals company Actavis Group...
-
REYKJAVIK, Iceland, Feb. 28, 2007 (PRIME NEWSWIRE) -- Actavis Group ("ACT"), the international generic pharmaceuticals company, announces its results for the fourth quarter and full year ended 31...
-
REYKJAVIK, Iceland, Feb. 14, 2007 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food...
-
REYKJAVIK, Iceland, Feb. 13, 2007 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, announced today that it has acquired the API (Active Pharmaceutical...
-
REYKJAVIK, Iceland, Feb. 12, 2007 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, today announces that a shareholders' meeting held here today has...
-
REYKJAVIK, Iceland, Feb. 7, 2007 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food &...
-
REYKJAVIK, Iceland, Dec. 21, 2006 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, announced today that it has bought back a total of 93 million shares,...
-
REYKJAVIK, Iceland, Nov. 30, 2006 (PRIME NEWSWIRE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, announced today that it has agreed to acquire Abrika Pharmaceuticals...
-
REYKJAVIK, Iceland, Nov. 21, 2006 (PRIMEZONE) -- Actavis Group (ICEX:ACT), the international generic pharmaceuticals company, announced today that it has acquired a 51% controlling interest in ZiO...